Cara Therapeutics traded at $8.62 this Friday July 1st, decreasing $0.51 or 5.59 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics lost 2.38 percent. Over the last 12 months, its price fell by 40.06 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 8.39 by the end of this quarter and at 7.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
8.62
Daily Change
-5.59%
Yearly
-40.06%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Chugai Pharma 3,529.00 53.00 1.52% -18.52%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
AcelRx Pharmaceuticals 0.26 0.01 5.61% -80.75%
Aerie Pharmaceuticals 8.36 0.86 11.47% -47.78%
Cara Therapeutics 8.62 -0.51 -5.59% -40.06%
Depomed 3.15 0.20 6.78% 115.75%
Endo International 0.57 0.10 22.42% -86.74%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Horizon Pharma 80.84 1.08 1.35% -15.68%
Jazz Pharmaceuticals 158.58 2.57 1.65% -12.63%
J&J 179.52 2.01 1.13% 6.24%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Pacira 57.85 -0.45 -0.77% -2.41%
Pfizer 52.31 -0.12 -0.23% 31.66%
Cassava Sciences Inc. 26.51 -1.61 -5.73% -70.56%
RedHill Biopharma 0.84 -0.03 -3.26% -87.94%
Revance Therapeutics 14.33 0.51 3.69% -52.85%
Supernus Pharmaceuticals 29.35 0.43 1.49% -3.36%
Teva Pharmaceutical Industries 7.89 0.37 4.92% -19.74%
Vanda Pharmaceuticals 11.19 0.29 2.66% -46.25%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Cara Therapeutics
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.